The study offers strong evidence for the role of GSNOR in EAE immunopathology and highlights the therapeutic potential of its inhibition. While the findings are compelling, it would be interesting to explore the broader implications of long-term GSNOR inhibition on immune homeostasis and whether the observed benefits of N91115 are influenced by variations in disease induction models. Could the authors address these aspects to provide a more comprehensive understanding of GSNOR’s therapeutic potential?
